The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

EXCLUSIVE: New mum Zara was shattered when told she had bowel cancer, but a new drug trial at The Christie in Manchester has ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type ...

Overview of Breast Cancer Therapeutics MarketThe Global Breast Cancer Therapeutics Market is valued at USD 33.83 Billion in ...

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

AEMD READ THE FULL AEMD RESEARCH REPORT Data Safety Monitoring Board Recommends Progressing Trial Without Modification Aethlon Medical’s (NASDAQ:AEMD) current primary focus is on researching lead ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...